L
Liang Shi
Researcher at Nanjing Medical University
Publications - 42
Citations - 1005
Liang Shi is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 14, co-authored 34 publications receiving 582 citations.
Papers
More filters
Journal ArticleDOI
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner
Jia-Yi Qian,Jian Gao,Xi Sun,Mengda Cao,Liang Shi,Tiansong Xia,Wenbin Zhou,Shui Wang,Qiang Ding,Ji-Fu Wei +9 more
TL;DR: The findings indicated that KIAA1429 could promote breast cancer progression and was correlated with pathogenesis, and may represent a promising therapeutic strategy on breast cancer, especially in combination with CDK1 treatment.
Journal ArticleDOI
PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer
Xu-Jie Zhou,Jing Wu,Liang Shi,Xiao-Xia Li,Lei Zhu,Xi Sun,Jia-Yi Qian,Ying Wang,Ji-Fu Wei,Qiang Ding +9 more
TL;DR: A new PTEN regulating mechanism was revealed that PTEN was positively regulated by R BM38 via stabilizing its transcript stability, which in turn alleviated RBM38-mediated growth suppression.
Journal ArticleDOI
Long noncoding RNA TRPM2-AS acts as a microRNA sponge of miR-612 to promote gastric cancer progression and radioresistance.
Jian Xiao,Linling Lin,Dakui Luo,Liang Shi,Wangwang Chen,Hao Fan,Zengliang Li,Xiang Ma,Peidong Ni,Li Yang,Zekuan Xu +10 more
TL;DR: Findings support a new regulatory axis between TRPM2-AS, miR-612, IGF2BP1, or FOXM1 which serve as crucial effectors in GC tumorigenesis and malignant development, suggesting a promising therapeutic and diagnostic direction for GC.
Journal ArticleDOI
miR-1254 inhibits cell proliferation, migration, and invasion by down-regulating Smurf1 in gastric cancer.
Mingkun Jiang,Liang Shi,Chao Yang,Chao Yang,Yugang Ge,Linling Lin,Hao Fan,Yu He,Diancai Zhang,Yongchang Miao,Li Yang +10 more
TL;DR: In summary, overexpression of miR-1254 could suppress proliferation, migration, invasion, and EMT via PI3K/AKT signaling pathways by downregulation of Smurf1 in GC, which suggests a potential therapeutic target for GC.
Journal ArticleDOI
MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
TL;DR: Overexpression of miR-592 promotes GC proliferation, migration, and invasion and induces the EMT via the PI3K/AKT and MAPK/ERK signaling pathways by inhibiting Spry2, suggesting a potential therapeutic target for GC.